The Evolving Definition of Comparative Effectiveness Research: Lessons for Researchers Planning and Designing a Clinical Development Program
Open Access Journal of Pharmaceutical Research · 2017
DOI: 10.23880/oajpr-16000125 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access Journal of Pharmaceutical Research, 2017. Verfasst von Greenberg PE.
Abstract (Originalsprache)
Among the many challenges that must be overcome in successfully developing a novel drug treatment is to understand and prepare evidence that will ultimately be required by regulators and reimbursement authorities. Payers and other stakeholders often state the need for evidence of the comparative effectiveness of new treatments, in some cases arguing that this evidence should be a standard requirement for market access and reimbursement. Comparative effectiveness research (CER) is a method of developing evidence of the clinical and cost effectiveness of true alternative interventions, potentially including long-term data that assess patientcentered outcomes and evidence that a new treatment actually changes clinical practice. Conceiving of and executing a plan for developing CER to support these evidence requirements is therefore a substantial challenge, one made even more difficult by evolving notions of CER and uncertainty in what constitutes sufficient evidence of comparative effectiveness. In fact, CER as a methodology is rapidly evolving, incorporating new sources of real-world and big data and applying cutting edge analytic techniques including novel statistical methods and machine learning [1]. This review aims to analyze the evolving conception of CER in order to support researchers and others in the life sciences industry in planning and designing a clinical development program to meet potential future requirements for CER that may increasingly determine commercial success. Early definitions of CER are often associated with the heightened attention and new funding that came with the American Recovery and Reinvestment Act (ARRA) of 2009 and with the establishment of the Patient-Centered Outcomes Research Institute (PCORI). Policy documents that established this view of CER argued for the importance of large prospective studies that could definitively establish the best (most effective) course of treatment [2-4]. More recently, definitions of CER have evolved to become more operational than theoretical, describing CER as a tool for a specific purpose; namely, to provide the specific evidence needed by clinicians, patients, policymakers, health plans, and other payers to make specific treatment and resource allocation decisions [5,6].
Zitieren
APA
PE, G. (2017). The Evolving Definition of Comparative Effectiveness Research: Lessons for Researchers Planning and Designing a Clinical Development Program. Open Access Journal of Pharmaceutical Research. https://doi.org/10.23880/oajpr-16000125
Vancouver
PE G. The Evolving Definition of Comparative Effectiveness Research: Lessons for Researchers Planning and Designing a Clinical Development Program. Open Access Journal of Pharmaceutical Research. 2017. doi:10.23880/oajpr-16000125
BibTeX
@article{PE2017,
author = {PE, Greenberg},
title = {The Evolving Definition of Comparative Effectiveness Research: Lessons for Researchers Planning and Designing a Clinical Development Program},
journal = {Open Access Journal of Pharmaceutical Research},
year = {2017},
doi = {10.23880/oajpr-16000125}
}
EUVIMED